{'fraction_non_alphanumeric': 0.029336734693877552, 'fraction_numerical': 0.016581632653061226, 'mean_word_length': 5.382113821138211, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical Effect and Metabolism of S‐Sulfonated Immunoglobulin in 7 Patients with Congenital Humoral Immunodeficiency

Abstract. 7 patients with primary humoral immunodeficiency were given an S‐sulfonated IgG preparation, 100 mg/kg i.v. at intervals of 3–4 weeks, for treatment of, or prophylaxis against, infection. The clinical effects and metabolism of S‐sulfonated IgG were studied. No side reactions attributable to S‐sulfonated IgG occurred in any of the patients. The S‐sulfonated IgG was completely transformed into intact IgG within 24 h after administration, and had a mean half‐life of 21 days, comparable to that of intact IgG. Complete restoration of IgG Fc fragment activity occurred within 24 h following injection, as assessed by reversed passive cutaneous anaphylaxis.